Keyphrases
Elderly Patients
100%
Lymphoma Patients
75%
Diffuse Large B-cell Lymphoma (DLBCL)
69%
Overall Survival
50%
High-dose Methotrexate (HD-MTX)
42%
Retrospective Analysis
42%
Hodgkin Lymphoma
38%
Progression-free Survival
37%
Relapsed or Refractory
35%
Follicular Lymphoma
32%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
32%
Positron Emission Tomography-computed Tomography (PET-CT)
32%
Rituximab
30%
Working Diagnosis
28%
Primary Central Nervous System Lymphoma (PCNSL)
28%
Acute Myeloid Leukemia
28%
Single Center
28%
Hodgkin
28%
COVID-19
28%
Chimeric Antigen Receptor T Cells (CAR-T)
28%
Chemotherapy
28%
Refractory Diffuse Large B-cell Lymphoma
25%
Young Patients
24%
Polatuzumab
23%
Israeli
22%
Partial Response
22%
Medical Center
22%
Cytarabine
21%
Radiotherapy
21%
Complete Response
19%
Oncology Patients
19%
Oncological Treatment
19%
Tel Aviv
17%
Thrombocytopenia
17%
High Risk
16%
Disease Progression
16%
Splenomegaly
15%
Chemoimmunotherapy
15%
Median Progression-free Survival
14%
Clinical High Risk
14%
Fear of COVID-19
14%
Occult
14%
Marijuana
14%
Predictive Value
14%
Patient Experience
14%
Cytogenetic Risk
14%
Treatment Adherence
14%
Cytomegalovirus
14%
Bone Marrow Involvement
14%
Interim PET-CT
14%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
64%
Hodgkin's Lymphoma
38%
Disease
38%
Overall Survival
37%
Elderly Patient
35%
Follicular Lymphoma
31%
Positron Emission Tomography-Computed Tomography
31%
Progression Free Survival
30%
Methotrexate
28%
COVID-19
28%
Positron Emission Tomography
28%
Cohort Analysis
28%
Chimeric Antigen Receptor T-Cell
28%
Radiation Therapy
21%
Drug Megadose
21%
Infection
20%
Rituximab
17%
Splenomegaly
17%
Lymphoproliferative Disease
17%
B Cell
16%
Chemoimmunotherapy
16%
Central Nervous System Disease
14%
Polatuzumab Vedotin
14%
CD20
14%
Prospective Study
14%
Patient with Inflammatory Bowel Disease
14%
Cytomegalovirus
14%
Cell Transplantation
14%
Hematologic Malignancy
14%
Janus Kinase 2
14%
Cannabis Use
14%
Gastrointestinal Tract
14%
Bone Mass
14%
Aggressive Lymphoma
14%
Breast Cancer Screening
14%
Myeloproliferative Neoplasm
14%
Mantle Cell Lymphoma
14%
Thrombocytopenia
14%
Intestine
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Hematopoietic Stem Cell
14%
Phlebothrombosis
14%
Computer Assisted Tomography
14%
Patient Experience
14%
Medical Cannabis
14%
Splenectomy
14%
Hairy Cell Leukemia
14%
Personal Experience
14%
Chimeric Antigen Receptor
14%
Symptom
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
56%
Overall Survival
50%
Infection
43%
Diffuse Large B Cell Lymphoma
40%
Progression Free Survival
38%
Disease
36%
Methotrexate
28%
Hodgkin Disease
28%
Remission
24%
Rituximab
23%
Primary Central Nervous System Lymphoma
20%
Cytarabine
17%
Thrombocytopenia
16%
Prospective Study
16%
Disease Exacerbation
16%
Splenomegaly
16%
Adverse Event
16%
Polatuzumab Vedotin
14%
Cytomegalovirus
14%
Cyclophosphamide
14%
Medical Cannabis
14%
Anticarcinogen
14%
Metastatic Colorectal Cancer
14%
Immune Dysregulation
14%
Ibrutinib
14%
Hematologic Malignancy
14%
Thiotepa
14%
Carmustine
14%
Coronavirinae
14%
Cefepime
14%
B Cell Lymphoma
14%
Acute Myeloid Leukemia
14%
Gemtuzumab Ozogamicin
14%
Chronic Lymphatic Leukemia
14%
Hairy Cell Leukemia
14%
Chimeric Antigen Receptor
14%
Disease Course
11%
Cannabis
11%
Retrospective Study
10%
Combination Therapy
10%
Remdesivir
9%
Infectious Complication
7%
Immunoglobulin A
7%
Clinical Feature
7%
Mucosa Inflammation
7%
Immunoglobulin Antibody
7%
Malignant Neoplasm
7%
Etoposide
7%
Neoplasm
7%
Symptom
6%